Authors: Mortada El-Sayed Ahmed
Polycystic ovary syndrome is a chronic low-grade inflammatory state that has an essential role in the future development of insulin resistance and other metabolic sequelae. C-reactive protein has an important role in oxidative stress and chronic low-grade inflammation; its chronic high level is considered one of the causes of PCOS long term consequences. This study was conducted to evaluate the role of Metformin therapy in lowering CRP levels in PCOS. 90 PCOS women were randomized to either 500 mg Metformin tablet 3 times daily for 6 months or placebo. Serum CRP levels decreased significantly in the Metformin group, 3.35 ± 0.99 mg/Litre to 2.58 ± 0.59 mg/Litre (P < 0.0001; 95% CI -1.121 to -0.419), with a significant difference between Metformin and placebo groups, 2.58 ± 0.59 mg/Litre vs 3.27 ± 1 mg/Litre respectively (P = 0.0001; 95% CI 0.346 to 1.034). In conclusion, Metformin is beneficial in lowering serum CRP in PCOS, thus, decreasing the chronic low-grade inflammatory state and decreasing risk of long term sequelae of PCOS.
Polycystic Ovary Syndrome, Metformin, Serum C-reactive protein
Download Full Paper
Effect of Metformin on Serum C-reactive protein in Polycystic Ovary Syndrome: A Randomized Controlled Trial